Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

This article was originally published on Nasdaq

QIAGEN N.V. QGEN is gaining from impressive sales growth in the non-COVID-19 product portfolio. The company’s earnings and revenues in the second quarter of 2022 were ahead of the Zacks Consensus Estimate. Robust instrument placements throughout the quarter instill optimi

Responses